Geographic Atrophy clinical trials at UCSF
2 in progress, 0 open to eligible people
A Study of NGM621 in Participants With Geographic Atrophy
Sorry, in progress, not accepting new patients
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
San Francisco, California and other locations
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
Sorry, in progress, not accepting new patients
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
San Francisco, California and other locations
Our lead scientists for Geographic Atrophy research studies include Jay M Stewart, MD.
Last updated: